AzTrials
AzTrials

PeriodontitisNCT07696845

C-PRF With Minimally Invasive Non-Surgical Periodontal Therapy

A study testing Minimally Invasive Non-Surgical Treatment and Concentrated Platelet-Rich Fibrin in people with Periodontitis and Intrabony Periodontal Defect, run by Altinbas University at 1 site in Turkey (Türkiye).

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This randomized controlled clinical study evaluated whether concentrated platelet-rich fibrin (C-PRF) provides additional clinical and radiographic benefits when used together with minimally invasive non-surgical periodontal treatment (MINST) in patients with advanced periodontitis and intrabony periodontal defects. Read more about this study

Who is it for?
Ages 18 to 70 years
What is being tested?
Minimally Invasive Non-Surgical Treatment and Concentrated Platelet-Rich Fibrin
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteTurkey (Türkiye)
Study dates
2 Aug 2026to 9 Feb 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Individuals aged 18 to 70 years.
  • Systemically healthy individuals.
  • Individuals diagnosed with Stage III or Stage IV periodontitis.
  • Presence of at least one periodontal intrabony defect with a radiographic intrabony defect depth of ≥3 mm.
  • Presence of probing pocket depth of ≥6 mm at the selected defect site.
  • No periapical pathology associated with the selected tooth.

Who cannot join

  • Pregnancy or lactation.
  • Presence of systemic diseases or use of medications that may affect periodontal healing.
  • Periodontal treatment within the recent period before enrollment.
  • Smoking ≥10 cigarettes per day.
  • Presence of periapical pathology associated with the selected tooth.

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Altınbaş University Faculty of Dentistry, Department of Periodontology

    Istanbul, Bakırkoy, 34147

Other trials in Turkey (Türkiye)

About this study

Official title: Clinical and Radiographic Evaluation of the Efficacy of Platelet-Rich Fibrin as an Adjunct to Minimally Invasive Non-Surgical Treatment in Individuals With Advanced Periodontitis

This randomized controlled clinical study evaluated whether concentrated platelet-rich fibrin (C-PRF) provides additional clinical and radiographic benefits when used together with minimally invasive non-surgical periodontal treatment (MINST) in patients with advanced periodontitis and intrabony periodontal defects.

Thirty systemically healthy patients with stage III-IV periodontitis were included. Each participant had at least one intrabony defect with a probing pocket depth of 6 mm or greater and a radiographic intrabony component of 3 mm or greater. Participants were randomly assigned to receive either MINST alone or MINST combined with C-PRF application.

Clinical periodontal measurements, including probing pocket depth, clinical attachment level, plaque score, bleeding on probing, and gingival recession, were recorded at baseline and at the 6-month follow-up. Standardized periapical radiographs were used to evaluate radiographic outcomes, including total defect depth, intrabony defect depth, defect angle, and linear bone fill.

Read the detailed description

Periodontitis is a chronic multifactorial inflammatory disease associated with dysbiotic dental biofilm and progressive destruction of the tooth-supporting tissues. In advanced periodontitis, vertical alveolar bone loss may result in periodontal intrabony defects. These defects are clinically important because they are commonly associated with deep periodontal pockets, clinical attachment loss, bleeding on probing, and increased risk of further periodontal breakdown if not adequately treated.

The management of periodontal intrabony defects traditionally includes non-surgical periodontal therapy as the initial treatment approach. However, in advanced cases, residual deep pockets and persistent inflammation may remain after conventional non-surgical therapy. Minimally invasive non-surgical treatment (MINST) has been proposed as a tissue-preserving approach for the management of intrabony periodontal defects. MINST aims to remove subgingival biofilm and calculus through careful instrumentation while minimizing trauma to the periodontal tissues. The technique emphasizes the preservation of the interdental papilla and marginal gingiva, limited tissue manipulation, avoidance of aggressive root planing and gingival curettage, and support of stable blood clot formation within the defect.

In this study, MINST is performed using fine periodontal instruments and thin ultrasonic tips without flap elevation. The objective of this approach is to achieve effective subgingival debridement while preserving soft tissue architecture and supporting periodontal wound healing. The minimally invasive nature of the procedure may be particularly relevant for patients with advanced periodontitis, where maintaining gingival tissue stability and reducing postoperative morbidity are important clinical goals.

Platelet-rich fibrin (PRF) is an autologous platelet concentrate obtained from the patient's own blood. PRF contains platelets, leukocytes, fibrin, and growth factors that may contribute to wound healing, angiogenesis, tissue repair, and periodontal regeneration. Concentrated platelet-rich fibrin (C-PRF) is a liquid PRF formulation prepared by collecting the cell-rich fraction from the buffy coat layer after centrifugation. Compared with liquid PRF protocols, C-PRF is designed to provide a higher concentration of platelets and leukocytes in a small volume, potentially increasing its biological activity at the application site.

Although several studies have evaluated different adjunctive biomaterials with minimally invasive periodontal therapy, evidence regarding the use of C-PRF together with MINST in advanced periodontitis remains limited. Therefore, this study is designed to evaluate whether the adjunctive application of C-PRF may provide additional clinical and radiographic benefits when combined with MINST in patients with stage III-IV periodontitis and periodontal intrabony defects.

This is a single-center, prospective, randomized controlled clinical study conducted as part of a doctoral thesis in the Department of Periodontology at Altinbas University. A total of 30 systemically healthy participants diagnosed with stage III-IV periodontitis are included. Each participant has at least one periodontal intrabony defect with a probing pocket depth of 6 mm or greater and a radiographic intrabony component of 3 mm or greater.

Participants are randomly allocated into two treatment groups. The control group receives MINST alone. The test group receives MINST followed by adjunctive C-PRF application into the periodontal pocket associated with the selected intrabony defect. For C-PRF preparation, venous blood is collected from the patient and processed according to the C-PRF protocol. The concentrated liquid fraction is then applied locally into the periodontal pocket after completion of the MINST procedure.

Clinical periodontal measurements are recorded at baseline and at the 6-month follow-up. The evaluated clinical parameters include probing pocket depth, clinical attachment level, plaque score, bleeding on probing, and gingival recession. Measurements are performed using standardized clinical methods, and site-specific values are recorded for the selected intrabony defect sites.

Radiographic assessment is performed using standardized periapical radiographs. Customized radiographic stents are used to improve reproducibility of radiographic image acquisition between baseline and follow-up. Radiographic measurements include total defect depth, intrabony defect depth, defect angle, linear bone fill, and defect fill percentage. These measurements are used to evaluate changes in the morphology and depth of the intrabony defects over the 6-month follow-up period.

Patient-reported outcome measures are also evaluated using visual analogue scale scores. These assessments are included to evaluate patient-centered outcomes such as pain, satisfaction, and aesthetic perception following treatment.

Being tested
Minimally Invasive Non-Surgical Treatment, Concentrated Platelet-Rich Fibrin
Keywords
Minimally Invasive Non-Surgical Treatment, Concentrated Platelet-Rich Fibrin, Intrabony Defects, Advanced Periodontitis
Medical subject headings
Periodontitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Minimally Invasive Non-Surgical TreatmentProcedure or surgery

    Also called MINST

    Minimally invasive non-surgical periodontal treatment was performed for the selected periodontal intrabony defect without flap elevation. Subgingival debridement was carried out using fine ultrasonic tips and mini-curettes. The procedure aimed to remove subgingival biofilm and calculus while preserving the interdental papilla, marginal gingiva, and soft tissue architecture, and supporting stable blood clot formation within the defect.

  • Concentrated Platelet-Rich FibrinBiological

    Also called C-PRF

    Concentrated platelet-rich fibrin was prepared from the participant's own venous blood according to the C-PRF protocol. After centrifugation, the concentrated liquid fraction was collected from the buffy coat region and applied locally into the periodontal pocket associated with the selected intrabony defect following completion of minimally invasive non-surgical periodontal treatment.

Study groups in NCT07696845
Study groupRoleWhat they receive
MINST AloneActive comparatorParticipants in this arm received minimally invasive non-surgical periodontal treatment (MINST) alone for the selected periodontal intrabony defect. Subgingival debridement was performed using fine ultrasonic tips and mini-curettes without flap elevation, with the aim of removing biofilm and calculus while preserving soft tissue architecture and supporting periodontal wound healing.
Receives: Procedure: Minimally Invasive Non-Surgical Treatment
MINST With C-PRFActive comparatorParticipants in this arm received minimally invasive non-surgical periodontal treatment (MINST) followed by adjunctive application of concentrated platelet-rich fibrin (C-PRF) into the periodontal pocket associated with the selected intrabony defect. C-PRF was prepared from the participant's own venous blood and applied locally after completion of the minimally invasive debridement procedure.
Receives: Procedure: Minimally Invasive Non-Surgical Treatment; Biological: Concentrated Platelet-Rich Fibrin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in probing pocket depth (PPD)

    Change in probing pocket depth (PPD) at the selected intrabony defect site from baseline to 6 months. PPD will be measured in millimeters using a UNC-15 periodontal probe.

    Measured: Baseline and 6 months

  2. Change in clinical attachment level (CAL)

    Change in clinical attachment level (CAL) at the selected intrabony defect site from baseline to 6 months. CAL will be measured in millimeters using a UNC-15 periodontal probe.

    Measured: Baseline and 6 months

Secondary outcomes (1)
  1. Change in radiographic intrabony defect depth

    Change in radiographic intrabony defect depth (IDD) from baseline to 6 months, measured on standardized periapical radiographs.

    Measured: Baseline and 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Jul 2026
  2. Study start2 Aug 2026
  3. Primary completion9 Feb 2027 (estimated)
  4. Study completion9 Feb 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants were randomly assigned to one of two parallel treatment groups: MINST alone or MINST combined with C-PRF application.
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07696845
Sponsor's protocol ID
MINST-CPRF-2026
Status last verified
Aug 2026
First submitted
3 Jul 2026
Last updated
19 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data will not be shared because the data contain confidential clinical information and were collected under ethical approval and informed consent for the purposes of this study only.

Questions about this trial

What is this clinical trial studying?

A study testing Minimally Invasive Non-Surgical Treatment and Concentrated Platelet-Rich Fibrin in people with Periodontitis and Intrabony Periodontal Defect, run by Altinbas University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 19 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in probing pocket depth (PPD) (time frame: Baseline and 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in